Author: Dino Mustafić

June 3, 2020 Off

Sygnature expands capabilities with acquisition of Alderley Oncology

By Dino Mustafić

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is further strengthening its oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for biotechs, pharmaceutical companies and academics.

June 3, 2020 Off

USFDA’s Coronavirus Q&A

By Dino Mustafić

The FDA is working to address the coronavirus disease (COVID-19) outbreak and keep you and your family informed on the latest developments. Here are answers to some frequently asked questions from consumers about testing:

June 3, 2020 Off

AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease

By Dino Mustafić

AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), said Wednesday that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington’s Disease (HD) were published in the peer-reviewed journal Neurobiology of Disease.

June 2, 2020 Off

Comar expands in NJ

By Dino Mustafić

Comar, a premier healthcare plastic packaging, device and component supplier, is pleased to announce a major capacity expansion of our Buena plant operations by building a new offsite location in Vineland, New Jersey.